Evidence map›Paper›PMID 41843104›Full record

Observational studyNeuroradiology2026

Impact of angiotensin-converting-enzyme inhibitors on intracranial aneurysm endovascular treatment outcome.

Kornelia M Kliś, Paweł Brzegowy, Antoni Cierniak, Igor Szydłowski, Aleksandra Midro, Roger M Krzyżewski, Borys M Kwinta, Krzysztof Stachura, Tadeusz J Popiela, Jerzy Gąsowski

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kornelia M KliśJagiellonian University, Krakow, Poland. kornelia.klis@uj.edu.pl.
Paweł BrzegowyJagiellonian University, Krakow, Poland.
Antoni CierniakJagiellonian University, Krakow, Poland.
Igor SzydłowskiVoivodeship Integrated Hospital in Kielce, Kielce, Poland.
Aleksandra MidroJagiellonian University, Krakow, Poland.
Roger M KrzyżewskiJagiellonian University, Krakow, Poland.
Borys M KwintaJagiellonian University, Krakow, Poland.
Krzysztof StachuraJagiellonian University, Krakow, Poland.
Tadeusz J PopielaJagiellonian University, Krakow, Poland.
Jerzy GąsowskiJagiellonian University, Krakow, Poland.

Funding

Narodowe Centrum Badań i Rozwoju LIDER13/0259/2022.
6 · The paper itself

Abstract

purposeAngiotensin-converting enzyme inhibitors (ACEis) are commonly prescribed antihypertensive medications. They also possess antiplatelet properties. The aim of this single-center retrospective observational cohort study was to analyze whether intake of ACEis may increase the risk of incomplete aneurysm occlusion after this treatment modality.

methodsWe retrospectively included patients hospitalized between January 2015 and June 2024 with unruptured intracranial aneurysm, who underwent endovascular treatment with coiling or Flow Diverter (FD) placement. Imaging data (at 6 months and 18 months follow-up) were collected. We gathered information about the occlusion status at both follow-up examinations. Univariate analysis was conducted using χ2 and t-tests, and multivariate analysis employed logistic regression.

resultsA total of 126 patients with 131 aneurysms were included in coiling group and 134 patients with 149 aneurysms were included in FD group. At baseline, ACEis were used by 49 patients in the coiling group and 40 patients in the flow diverter group. Patients treated with flow diversion or stent-assisted coiling received standard antiplatelet therapy and none were on oral anticoagulation. The most commonly used ACEis were ramipril (57.30%), perindopril (32.58%), and lisinopril (10.11%). Twenty-six aneurysms (19.9%) from the coiling group were recanalized on the first follow-up examination. Patients with recanalized aneurysms were significantly more likely to take ACEis (61.54% vs. 31.43%; p < 0.01). In multivariable analysis, the logistic regression model identified aneurysm ACEis intake (OR:3.65;95% CI:1.2–11.83;p = 0.02) as an independent predictor of aneurysm recanalization at the first follow-up. Sixty-eight aneurysms (45.64%) from the FD group were incompletely occluded at the first follow-up examination. Similarly to coiling group, patients with non-totally occluded aneurysms were more likely to take ACEis (36.76% vs. 18.51%;p = 0.01). In multivariate analysis, intake of ACEis (OR:2.86;95% CI:1.34–6.29;p < 0.01) significantly increased risk of incomplete occlusion at first follow-up.

conclusionsACEis intake might reduce the rate of total aneurysm occlusion after endovascular treatment.

Indexed as

Angiotensin-Converting Enzyme InhibitorsEndovascular ProceduresIntracranial AneurysmAgedCerebral AngiographyFemaleHumansMaleMiddle AgedRetrospective StudiesStentsTreatment OutcomeAngiotensin-Converting Enzyme InhibitorsAntihypertensive medicationsEndovascular treatmentFlow DiverterIntracranial aneurysmTreatment outcome

Identifiers

PMID41843104

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.